论文部分内容阅读
辅助化疗在防止胃癌术后的复发和延长存活中起着重要作用。本文首次报导在多个中心进行的关于左旋咪唑(LMS)作为胃癌手术辅助治疗的前瞻性随机对照研究。病例为1979.1～1981.3在日本10个医院进行胃切除的胃癌患者。术前将病例随机地分为二组[LMS(+)或LMS(-)]。二者均于手术当日静脉给予丝裂霉素20mg,次日再给10mg,术后第二周开始每日用Tegafur 600mg,达一年或一年以上.LMS(+)组术前用LMS(150mg/日)三天,术后第二周开始,按三日用药(150mg/日)随后十一日间歇的方案,给药一年或一年以上。共研究222例病人,其中67例因各种原因而被剔除。可供分析的病例为156例,LMS(-)组77例,LMS(+)组78例。二组病人特征的分布不存在统计学差异和偏差。
Adjuvant chemotherapy plays an important role in preventing postoperative recurrence and prolonging survival of gastric cancer. This paper reports for the first time a prospective randomized controlled trial of levamisole (LMS) as adjuvant therapy for gastric cancer performed at multiple centers. The cases were gastric cancer patients undergoing gastrectomy at 10 hospitals in Japan from January 1979 to September 1981.3. Patients were randomly divided into two groups [LMS (+) or LMS (-)] before surgery. Both received intravenous mitomycin 20 mg on the same day of surgery and 10 mg the next day. Tegafur 600 mg daily for the first week after surgery was administered for one year or more. LMS (+) group was preoperatively treated with LMS ( 150 mg/day) for three days, starting at the second week after surgery, three days of medication (150 mg/day) followed by an 11-day intermittent regimen, administered one year or more. A total of 222 patients were studied, 67 of which were excluded for various reasons. There were 156 cases available for analysis, 77 cases in the LMS(-) group, and 78 cases in the LMS(+) group. There was no statistical difference or bias in the distribution of the characteristics of the two groups of patients.